Format

Send to

Choose Destination
Medwave. 2015 Apr 6;15(3):e6115. doi: 10.5867/medwave.2015.03.6115.

[Testosterone replacement therapy and prostate cancer: the downfall of a paradigm?].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Unidad de Urología, Clínica INDISA, Santiago, Chile; Facultad de Medicina, Universidad Andrés Bello, Santiago, Chile. Address: Av. Santa María #1810, Providencia, Santiago, Chile. Email: ivarvidal@gmail.com.
2
Unidad de Urología, Clínica INDISA, Santiago, Chile.
3
Cátedra de Urología, Facultad Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina.

Abstract

in English, Spanish

For six decades, it has been a part of the conventional medical wisdom that higher levels of testosterone increase the risk of prostate cancer. This belief is mostly derived from the well-documented regression of prostate cancer after surgical or pharmacological castration. However, there is an absence of scientific data supporting the concept that higher testosterone levels are associated with an increased risk of prostate cancer. Moreover, men with hypogonadism have substantial rates of prostate cancer in prostatic biopsies, suggesting that low testosterone has no protective effect against the development of prostate cancer. Moreover, prostate cancer rate is higher in elderly patients when hormonal levels are low. These results argue against an increased risk of prostate cancer with testosterone replacement therapy.

KEYWORDS:

familial; testosterone; hypogonadism; hormone replacement therapy; prostate cancer

PMID:
25919660
DOI:
10.5867/medwave.2015.03.6115
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center